Check 35,000+ stocks against 26 valuation models and 37 quality factors

Shanghai Tofflon Science Tech (300171) fair value: what the stock is really worth

As of Sep 22, 2026: fair value of Shanghai Tofflon Science Tech ¥6.72, price ¥15.81, upside -57.5%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? Yes
Add to watchlist

Healthcare · CN · ISIN CNE100000ZP0

ST Some data Sep 24, 2026

Shanghai Tofflon Science Tech

300171 · SHE

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value ¥6.72 · Strongly overvalued (−58%)

!Quality 54/100

!Mixed Growth (revenue 5y +14.1 %/yr)

!Thin margins · 4.0% net margin (TTM)

✓Low debt · generates free cash flow

·0.70% dividend yield

!Trails peers (4/13)

!Narrow moat 34/100

!Evidence only medium, so the estimate is less certain

!Weak on past: 11 out of 100

!Weak on dividend: 14 out of 100

26 models, one by oneBear ¥6.72 to bull ¥8.73 Growth analysisrevenue history, year by year Quality 54/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Shanghai Tofflon Science Tech for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range ¥9.50 – ¥58.85 · fair‑value band ¥6.72 – ¥8.73 · the ¥15.81 price screens above the ¥6.72 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Shanghai Tofflon Science Tech in your weekly email

Every Wednesday you see whether Shanghai Tofflon Science Tech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tofflon Science and Technology Group Co., Ltd. engages in the research, development, production, sales, and services of pharmaceutical equipment in China and internationally. It operates through four segments: Biotechnology, Preparation Equipment, Engineering, and Food Engineering. The company offers technological research, such as cell technology, complex preparation, injection, and OSD laboratory; instruments, including cell therapy and nucleic acid drugs instruments, and table reactor; cryopreservation system for seeds and biological samples, and freeze-thaw system of biological stock solution; and single use technology, such as bioreactor, liquid distribution system, sterile bag, process chromatography, membrane filtration system, and others. It also provides culture medium, such as cell and gene therapy, biomacromolecule drugs, tobitec feeding medium, and other series; bioreactor and fermentation systems, cell factory, perfusion, and complementary systems; preparation systems, such as bio-process vessel and piping, common solutions, and complex injectable formulation systems; and separation and purification systems, including disc centrifuge membrane filtration, chromatography system and columns, alkali lysis, slurry tank, and filters. In addition, the company offers freeze-drying system, including laboratory, production, and special application freeze-drying products, as well as loading and unloading system; and packaging systems, such as packaging solutions, cartoner machine, top-load cartoner machines, bilster machine, solid bottling equipment, labelling machine, and case packer with palletizer machines. Further, it provides resins, API, isolator system, cleaning and sterilization, filling line, and inspection system products; and engineering services. The company was formerly known as Shanghai Tofflon Science and Technology Co., Ltd. Tofflon Science and Technology Group Co., Ltd. was founded in 1993 and is headquartered in Shanghai, China.

Stock analysis

Shanghai Tofflon Science Tech (300171) currently trades at ¥15.81, while our model-based Fair Value estimate is ¥6.72, implying the stock looks roughly 135.3% overvalued today.

Valuation

Bull case: the DCF Models group reads highest at a median of ¥13.64 per share, and 4 of the 26 models we run sit above the ¥15.81 price.

Bear case: the Dividend Discount group reads lowest at ¥1.37, and 22 of the 26 models stay below the price. Evidence for this calculation is medium.

Scenario range: ¥6.72 (bear) to ¥8.73 (bull), the price of ¥15.81 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Shanghai Tofflon Science Tech reported revenue of 5.2B CNY in FY2025 versus 4.2B CNY in FY2021, a compound +5.7%/yr. Reported net income was 200M CNY in FY2025, compounding −29.9%/yr from FY2021.

Key figures

Market cap 12.1B CNY (≈ $1.8B) · P/E ratio 58.6 · P/S ratio 2.24 · EPS (TTM) ¥0.2700 · Dividend yield 0.7% · Net margin 3.8% · Return on equity 2.7% · Return on assets (EBIT) 5.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (medium confidence).

What moves the price

The share trades about 13% below its 52-week high and 47% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −58%, 300171 screens richer than that median.

Fair Value models

Bear ¥6.72 Fair Value ¥6.72 Bull ¥8.73

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.1170 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF ¥11.24 ¥15.94 ¥27.21 79

Owner Earnings ¥5.32 ¥6.59 ¥8.82 78

Growth DCF ¥10.95 ¥16.72 ¥25.58 78

All 26 models by family

DCF Models

FCF DCF ¥11.24 ¥15.94 ¥27.21 79

Owner Earnings ¥5.32 ¥6.59 ¥8.82 78

5Y Revenue Exit ¥9.03 ¥12.84 ¥18.48 73

5Y EBITDA Exit ¥10.55 ¥16.24 ¥24.23 74

5Y P/E Exit ¥9.14 ¥13.21 ¥18.14 71

10Y Revenue Exit ¥9.62 ¥13.64 ¥19.54 67

10Y EBITDA Exit ¥10.70 ¥16.09 ¥25.16 67

10Y P/E Exit ¥9.81 ¥13.82 ¥20.02 64

Earnings-Based

Graham-Dodd ¥1.78 ¥11.20 ¥15.64 63

Lynch FV ¥3.23 ¥4.61 ¥6.00 61

PEG = 1.0 ¥3.23 ¥4.61 ¥6.00 57

EPV ¥7.04 ¥7.45 ¥7.80 74

Dividend Discount

Gordon GGM ¥0.8300 ¥1.50 ¥2.06 68

DDM Multi-Stage ¥0.8300 ¥1.37 ¥1.60 67

Multiples

P/E Multiple ¥4.32 ¥5.76 ¥7.20 63

P/S Multiple ¥3.34 ¥4.45 ¥5.56 58

P/B Multiple ¥3.34 ¥4.45 ¥5.56 55

EV/EBIT ¥9.39 ¥11.20 ¥13.00 66

EV/EBITDA ¥10.56 ¥12.75 ¥14.94 67

EV/Revenue ¥7.84 ¥9.50 ¥11.15 54

Asset-Based

NCAV (Graham) ¥5.18 ¥6.94 ¥10.36 54

Growth DCF

Growth DCF ¥10.95 ¥16.72 ¥25.58 78

Rev-Margin DCF ¥9.03 ¥12.85 ¥18.29 73

Economic Profit

Residual Income ¥6.97 ¥6.56 ¥4.96 76

ROIC Compounder ¥7.04 ¥7.45 ¥7.80 72

Growth Earnings

Growth-Adj P/E ¥4.70 ¥6.71 ¥8.73 67

Open the full fair value analysis →

Notify me when 300171 reaches fair value

Put 300171 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 54/100

Of which business quality 55 · Market factors (momentum, volatility) 59

Profitability 23

Margins and returns on capital today

Quality Growth 43

Are margins and returns improving?

Cashflow 62

Earnings quality: real cash, not paper profit

Fin. Strength 85

Balance sheet, leverage, solvency risk

Investment 90

Disciplined investing over empire-building

Low Volatility 71

Calm price path (market factor)

Momentum 54

Price trend over the last 3–12 months (market factor)

52W Momentum 55

Distance to the 52-week high (market factor)

Net Issuance 35

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 90/100

Revenue is growing, but margins or cash flow do not fully confirm the trend.

Revenue growth 1 year

+4.4%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−1.5%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+14.1%

Start year 2020 (pandemic). Over 10 years: +12.9% a year

Revenue growth 18 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+21.1%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.

−18.0%

Earnings growth per share plus dividend.

Earnings per share, growth per year−18.7%

Dividend (yield on the price)0.7%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−19% vs −7%, slowing

Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 6%

Start year 2020 (pandemic)

Growth Forecast

Price in line with expectations

The price assumes about as much growth as the company has delivered so far.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+11.4%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect

n/a

No analyst forecast available.

After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +9.6% a year for the price.

300171 screens 135% overvalued. Compare with Intuitive Surgical, Inc →

Compare Shanghai Tofflon Science Tech with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks

Beats the industry median on 4/13 measures

Overall it trails its industry peers.

Valuation

Quality Score 54 · Below median

Fair Value upside −58% · Bottom 25%

Profitability

Return on equity (TTM) 3% · Below median

Return on assets 1% · Below median

Net margin (TTM) 4% · Below median

Operating margin (TTM) 6% · Below median

Growth and dividend

Revenue growth −3% · Bottom 25%

Dividend yield (TTM) 0.7% · Bottom 25%

Balance sheet

Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 58.6× · Priciest 25%

P/B 0.23× · Cheapest 25%

P/S (TTM) 0.35× · Cheapest 25%

P/FCF 3.9× · Cheaper than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 15

FUTURE (revenue growth)0 · sector 31

PAST (return on equity)11 · sector 25

HEALTH (low debt)100 · sector 96

DIVIDEND (yield)14 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Intuitive Surgical, Inc ISRG	$402.09	$353.38	−12%
EssilorLuxottica Société anonyme EL	€144.50	€158.95	+10%
Medline Inc MDLN	$34.43	$30.15	−12%
Becton, Dickinson and Company BDX	$183.00	$103.53	−43%
Alcon Inc ALC	$65.59	$39.78	−39%
ResMed Inc RMD	A$31.61	A$34.77	+10%
West Pharmaceutical Services, Inc WST	$371.09	$137.28	−63%
Sartorius Stedim Biotech S.A DIM	€206.40	€54.82	−73%
Straumann Holding STMN	CHF 97.86	CHF 45.50	−54%
Solventum Corporation SOLV	$88.75	$130.51	+47%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shanghai Tofflon Science Tech · Fair Value
¥6.72 −135%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/300171" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Shanghai Tofflon Science Tech · Fair Value</span><br><b style="font-size:20px">¥6.72</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−135%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Shanghai Tofflon Science Tech Fair Value". https://www.fairvalue-calculator.com/stock/300171

Frequently asked questions

Is Shanghai Tofflon Science Tech (300171) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of ¥6.72 versus a price of ¥15.81, about −58% upside (overvalued).

What is the fair value of 300171?

Our model-based fair value for Shanghai Tofflon Science Tech is ¥6.72 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥15.81.

What is the quality score of 300171?

Shanghai Tofflon Science Tech has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Shanghai Tofflon Science Tech (300171)?

Our model-based price target is the fair value of ¥6.72 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario ¥6.72, optimistic scenario ¥8.73. It is a calculation from audited fundamentals, not an analyst target.

What is the Shanghai Tofflon Science Tech stock forecast for 2026?

Our models put fair value at ¥6.72, about −58% upside versus a price of ¥15.81 (overvalued). Cautious scenario ¥6.72, optimistic scenario ¥8.73. The calculation is refreshed regularly with new filings.

What is the revenue of Shanghai Tofflon Science Tech (300171)?

Shanghai Tofflon Science Tech reported trailing-twelve-month revenue of about 5.2B CNY (latest available figure, as of Sep 24, 2026).

Does Shanghai Tofflon Science Tech pay a dividend?

Shanghai Tofflon Science Tech currently shows a dividend yield of about 0.70% relative to its recent price (as of Sep 24, 2026).

What growth is priced into Shanghai Tofflon Science Tech (300171)?

For today's price to be fair in a discounted-cash-flow model, Shanghai Tofflon Science Tech would have to grow free cash flow by +11.4 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.1 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of 300171 use?

Our models discount Shanghai Tofflon Science Tech at 10.4 %: a base by market capitalisation (small), damped by beta 0.25, country premium for China. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Shanghai Tofflon Science Tech that is +11.4 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.

How much growth has Shanghai Tofflon Science Tech (300171) delivered so far?

Over the past 5 years revenue at Shanghai Tofflon Science Tech grew +14.1 % a year. The price currently implies +11.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of Shanghai Tofflon Science Tech (300171) growing?

The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Shanghai Tofflon Science Tech (+11.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of Shanghai Tofflon Science Tech (300171)?

The free-cash-flow yield on the price is 3.80 %: that much free cash flow Shanghai Tofflon Science Tech produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of Shanghai Tofflon Science Tech (300171)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Tofflon Science Tech it is ¥6.72 per share (as of Sep 24, 2026), against a price of ¥15.81. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is Shanghai Tofflon Science Tech stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 300171 trades above its calculated fair value: price ¥15.81, fair value ¥6.72, a gap of about −58% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 300171?

No. The price is what the market pays today (¥15.81); the fair value is what the company's own numbers justify (¥6.72). For Shanghai Tofflon Science Tech the two are ¥9.09 per share apart. That gap is exactly why we show both numbers side by side.

How much is Shanghai Tofflon Science Tech worth?

The market values Shanghai Tofflon Science Tech at about 12.1B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥15.81; our models calculate a fair value of ¥6.72 per share.

What do the bullish and bearish scenarios say about 300171?

Our models span a range for Shanghai Tofflon Science Tech: cautious scenario ¥6.72, base ¥6.72, optimistic ¥8.73 per share (as of Sep 24, 2026, price ¥15.81). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 300171?

Shanghai Tofflon Science Tech trades at a price-to-earnings ratio of 58.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥6.72 is built from several models across several years. Other multiples: P/B 0.2, P/S 0.3.

How solid is the balance sheet of Shanghai Tofflon Science Tech (300171)?

Balance-sheet figures for Shanghai Tofflon Science Tech (as of Sep 24, 2026): return on equity 2.7%, debt of 0.01 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.

How far is 300171 from its 52-week high?

Shanghai Tofflon Science Tech trades at ¥15.81, about 13% below its 52-week high of ¥18.08 and 47% above the low of ¥10.77 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥6.72 is for.

Which stocks are comparable to Shanghai Tofflon Science Tech?

From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Shanghai Tofflon Science Tech stock attractive at the current price?

The data as of Sep 24, 2026: price ¥15.81, calculated fair value ¥6.72 (−58%), Quality Score 54/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 300171 calculated?

We run Shanghai Tofflon Science Tech through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥6.72, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.1 % above its aggregate fair value. Shanghai Tofflon Science Tech itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Shanghai Tofflon Science Tech (300171)?

The closing price on Sep 22, 2026 was ¥15.81. Our model-based fair value is ¥6.72, about −58% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Shanghai Tofflon Science Tech right now?

The price sits above even our optimistic bull case (¥8.73). The favourable scenario is already priced in. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.

Where does the earnings growth of Shanghai Tofflon Science Tech (300171) come from?

Earnings per share at Shanghai Tofflon Science Tech grew +4.2 % a year from 2013 to 2024. Broken into its drivers: revenue per share +15.5 %, EBIT margin −9.7 %, tax rate +0.7 %, residual (interest, one-offs) −0.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Shanghai Tofflon Science Tech

How large is the market capitalisation of Shanghai Tofflon Science Tech (300171)?

The market capitalisation of Shanghai Tofflon Science Tech is 12.1B CNY (≈ $1.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Shanghai Tofflon Science Tech (300171)?

The price-to-sales ratio of Shanghai Tofflon Science Tech is 2.24 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Shanghai Tofflon Science Tech (300171)?

Earnings per share at Shanghai Tofflon Science Tech are ¥0.2700 (price ÷ EPS = P/E 58.6). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Shanghai Tofflon Science Tech (300171)?

The dividend yield of Shanghai Tofflon Science Tech is 0.7% (payout 40.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Shanghai Tofflon Science Tech (300171)?

The net margin of Shanghai Tofflon Science Tech is 3.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Shanghai Tofflon Science Tech (300171)?

The return on equity (ROE) of Shanghai Tofflon Science Tech is 2.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Shanghai Tofflon Science Tech (300171)?

On an EBIT basis the return on assets of Shanghai Tofflon Science Tech is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Shanghai Tofflon Science Tech (300171)?

The operating margin of Shanghai Tofflon Science Tech is 5.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Shanghai Tofflon Science Tech (300171)?

Revenue at Shanghai Tofflon Science Tech is growing −2.5% versus a year earlier (3y avg −1.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Shanghai Tofflon Science Tech (300171)?

Earnings per share at Shanghai Tofflon Science Tech are growing +37.6% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does Shanghai Tofflon Science Tech (300171) hold?

Shanghai Tofflon Science Tech holds more cash than debt, 2.5B CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Shanghai Tofflon Science Tech in the live analysis

One click puts Shanghai Tofflon Science Tech on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.